Atlas Trials

Hurler-Scheie Syndrome

11 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Hurler-Scheie Syndrome

RecordFirmDate
RGX-111 Gene Therapy in Patients With MPS I (NCT03580083)REGENXBIO Inc.2019-04-03
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders (NCT01372228)Talaris Therapeutics Inc.2011-04-01
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants (NCT00418821)Genzyme, a Sanofi Company2010-10-22
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I (NCT00852358)Patricia I. Dickson, M.D.2009-06-01
Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I (NCT00786968)Patricia I. Dickson, M.D.2008-01-01
Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease (NCT00258011)Genzyme, a Sanofi Company2005-12-01
A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease (NCT00144781)Genzyme, a Sanofi Company2004-12-01
A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients (NCT00144768)Genzyme, a Sanofi Company2004-07-01
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old (NCT00146757)Genzyme, a Sanofi Company2002-10-01
Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients (NCT00146770)Genzyme, a Sanofi Company2001-05-01
Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I (NCT00912925)Genzyme, a Sanofi Company2000-12-01

Track Hurler-Scheie Syndrome automatically

Every clearance here is in the API, with alerts when new ones post.